Hospital
Ascension Borgess Lee Hospital
Ascension Borgess Lee Hospital was paid $6.88M by Medicaid between Jan 2018 and Dec 2024, across 128 billing codes. Its largest line is 99283, emergency room visit (moderate) — 27% of everything it billed.
33Billing provider infoASCENSION BORGESS LEE HOSPITAL
DOWAGIAC, MI 49047
DOWAGIAC, MI 49047
33aNPI1194771030assigned 05/25/2006
33bProvider typeMedicare Defined Swing Bed Hospital Unit
28Total paid$6.88M
24GClaims168,234
24DCodes billed128
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Medicare Defined Swing Bed Hospital Unit providers in Michigan
Rank by total paid#3 of 8
Median peer was paid$5.78M
This provider vs. median1.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official HOUGHTON, MARINA controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 30,194 | $854K | |
| 2019 | 26,848 | $789K | |
| 2020 | 21,882 | $935K | |
| 2021 | 27,326 | $1.22M | |
| 2022 | 22,513 | $1.04M | |
| 2023 | 25,438 | $1.18M | |
| 2024incomplete | 14,033 | $861K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 27% | 11,827 | 11,255 | $1.89M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 21% | 6,366 | 6,009 | $1.43M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 19% | 3,623 | 3,425 | $1.33M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 6.5% | 3,834 | 3,546 | $449K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.7% | 2,778 | 2,718 | $251K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.4% | 1,912 | 1,016 | $232K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.6% | 6,206 | 1,621 | $178K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.6% | 2,749 | 2,504 | $109K |
| 71046 | Radiologic examination, chest; 2 views | 1.5% | 4,032 | 2,095 | $102K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.4% | 1,028 | 545 | $95K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.4% | 2,649 | 2,568 | $93K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.1% | 1,278 | 680 | $73K |
116 more codes
| 71045 | Radiologic examination, chest; single view | 1.0% | 2,850 | $69K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,045 | $66K |
| 80053 | Comprehensive metabolic panel | <1% | 11,975 | $35K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,394 | $34K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 682 | $33K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 3,560 | $26K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 13,008 | $25K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,608 | $22K |
| 97161 | <1% | 398 | $21K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 511 | $20K |
| 80061 | Lipid panel | <1% | 2,014 | $19K |
| 72100 | <1% | 744 | $18K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 3,775 | $17K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,481 | $15K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,130 | $15K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,130 | $15K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,866 | $14K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 122 | $14K |
| 82465 | <1% | 1,375 | $10K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 26 | $10K |
| G0378 | Hospital observation service, per hour | <1% | 12 | $8K |
| 36415 | Collection of venous blood by venipuncture | <1% | 9,004 | $7K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 513 | $7K |
| 73630 | <1% | 673 | $7K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 379 | $6K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,920 | $6K |
| 82947 | <1% | 330 | $6K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 58 | $6K |
| 73562 | <1% | 362 | $6K | |
| 83718 | <1% | 1,362 | $5K | |
| 83880 | <1% | 695 | $5K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 21 | $5K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,844 | $5K |
| 84478 | <1% | 1,398 | $4K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 99 | $4K |
| 82607 | <1% | 611 | $4K | |
| 73610 | <1% | 504 | $4K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,442 | $4K |
| 73130 | <1% | 498 | $4K | |
| 73030 | <1% | 283 | $3K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,026 | $3K |
| 84439 | <1% | 617 | $3K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 173 | $2K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,664 | $2K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,540 | $2K |
| 83690 | <1% | 2,354 | $2K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 51 | $2K |
| 93975 | <1% | 25 | $2K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 49 | $2K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 63 | $2K |
| 74018 | <1% | 158 | $2K | |
| 87186 | <1% | 657 | $2K | |
| 85610 | <1% | 1,747 | $1K | |
| 81001 | <1% | 3,767 | $936.41 | |
| 73110 | <1% | 61 | $893.72 | |
| 83735 | <1% | 1,107 | $865.66 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 33 | $763.54 |
| 84481 | <1% | 87 | $555.06 | |
| 85027 | <1% | 197 | $547.58 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 536 | $531.50 |
| 82550 | <1% | 271 | $475.94 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 35 | $451.77 |
| 87581 | <1% | 21 | $450.99 | |
| 87486 | <1% | 21 | $450.99 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 648 | $449.09 |
| 81003 | <1% | 2,115 | $445.11 | |
| 72070 | <1% | 26 | $442.28 | |
| 84484 | <1% | 1,908 | $438.39 | |
| 81025 | <1% | 3,057 | $385.34 | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 39 | $368.82 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,387 | $336.14 |
| 85730 | <1% | 1,065 | $320.95 | |
| 82728 | <1% | 38 | $243.21 | |
| 87077 | <1% | 97 | $227.73 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 358 | $154.69 |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 15 | $138.80 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,748 | $136.88 |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 131 | $126.18 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 3,053 | $115.20 |
| 83540 | <1% | 40 | $113.74 | |
| 83605 | <1% | 457 | $76.07 | |
| 81002 | <1% | 34 | $74.36 | |
| 84702 | <1% | 25 | $66.22 | |
| 85652 | <1% | 52 | $53.43 | |
| 86140 | <1% | 29 | $53.20 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 782 | $52.59 |
| 87070 | <1% | 27 | $49.16 | |
| 82043 | <1% | 12 | $40.77 | |
| 85379 | <1% | 117 | $40.70 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,015 | $40.27 |
| 87634 | <1% | 119 | $31.80 | |
| 87088 | <1% | 16 | $30.15 | |
| 86431 | <1% | 12 | $23.10 | |
| 87040 | <1% | 58 | $22.32 | |
| 86038 | <1% | 12 | $17.75 | |
| 80143 | <1% | 64 | $15.44 | |
| 80179 | <1% | 64 | $15.44 | |
| 87807 | <1% | 75 | $6.51 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,515 | $1.94 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 193 | $1.67 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 162 | $1.34 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 128 | $0.85 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 171 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 12 | $0.00 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 33 | $0.00 |
| 87254 | 0% | 227 | $0.00 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 16 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 16 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 97 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 399 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 73 | $0.00 |
| 96376 | 0% | 67 | $0.00 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 122 | $0.00 |
| 87280 | 0% | 16 | $0.00 | |
| J2060 | Injection, lorazepam, 2 mg | 0% | 33 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHOUGHTON, MARINA (CFO)
| Provider | Location | Paid |
|---|---|---|
| Ascension Borgess Hospital | Kalamazoo, MI | $43.08M |
| Ascension Medical Group Promed | Kalamazoo, MI | $10.60M |
| Ascension Medical Group Promed | Portage, MI | $7.97M |
| Ascension Borgess Allegan Hospital | Allegan, MI | $6.03M |
| Ascension Borgess Hospital | Plainwell, MI | $4.84M |
| Ascension Borgess Allegan Hospital | Allegan, MI | $3.71M |
| Ascension Borgess Hospital | Plainwell, MI | $3.71M |
| Ascension Borgess Lee Hospital | Dowagiac, MI | $2.70M |
| Ascension Medical Group Promed | Kalamazoo, MI | $2.55M |
| Ascension Medical Group Promed | Portage, MI | $2.07M |
| Ascension Medical Group Promed | Portage, MI | $1.64M |
| Ascension Borgess Lee Hospital | Dowagiac, MI | $1.58M |
| Ascension Borgess Hospital | Portage, MI | $1.22M |
| Ascension Borgess Allegan Hospital | Gobles, MI | $298K |
| Ascension Borgess Allegan Hospital | Otsego, MI | $294K |
| Ascension Borgess Allegan Hospital | Fennville, MI | $246K |
| Ascension Borgess Hospital | Kalamazoo, MI | $91K |
| Ascension Borgess Allegan Hospital | Allegan, MI | $55K |
| Ascension Borgess Allegan Hospital | Allegan, MI | $43K |
| Ascension Borgess Hospital | Kalamazoo, MI | $40K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.